Don Dizon, MD on the Experiences of Gay and Transgender Patients With Cancer

Article

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, emphasizes the experience of lesbian, gay, bisexual, and transgender patients with cancer and negative interactions that can impact their cancer care experience.

Transcript:

What people may not realize, particularly my colleagues, is that any person who identifies as lesbian or gay or bisexual or trans[gender], every single time they meet a new doctor, there’s that moment of anxiety of, ‘Do I need to come out to this person? Are they going to ask me? What are going to be the repercussions if I do?’ Now imagine that someone is being treated for cancer, which is a multidisciplinary treated disease these days. You’re not only meeting an oncologist; you’re meeting nursing staff, infusion staff, navigators, [and] medical assistants, in addition to a medical oncologist, a radiation oncologist, and even a surgeon. All those time points, do you need to come out? It’s really quite daunting. All you need is 1 event where that [patient] was treated with disrespect and it can color the whole experience for that person. And not in good ways.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content